CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.

Related Videos